ReviewFrontiers in immunology2026
The role of metabolic crosstalk between Intestinal epithelial cells and immune cells in inflammatory bowel disease and targeting strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammatory disorder characterized by disruption of the intestinal epithelial barrier and dysregulated immune responses. IBD pathogenesis is intricately linked to the metabolic reprogramming of the intestinal epithelial cells (IECs), which are central to both barrier maintenance and immune crosstalk. Mitochondrial dysfunction in the IECs leads to energy deficit, oxidative stress, and barrier failure, which activates the adjacent immune cells and establishes a vicious cycle of inflammation. This review focuses on the key role of the mitochondrial metabolism in IBD with a specific focus on the remodeling of the glucose, lipid, and amino acid metabolic pathways in epithelial and immune cells. We elaborate on the specific regulatory mechanisms underlying these metabolic processes and the functions of metabolic products as signaling molecules in cell-cell communication. In addition to causing energy crises and barrier defects in epithelial cells, metabolic remodeling directly controls the activation of immune cells and their polarization toward a pro-inflammatory phenotype. Thus, a deeper understanding of mitochondrial metabolism underlying IBD would provide a crucial theoretical foundation for developing novel precision therapies targeting metabolism. Additionally, elucidating these metabolic networks would provide new therapeutic opportunities for restoring homeostasis in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.